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Background: The molecular mechanisms underlying the potential health benefits of a ketogenic diet are
unknown and could be mediated by epigenetic mechanisms.
Objective: To identify the changes in the obesity-related methylome that are mediated by the induced
weight loss or are dependent on ketosis in subjects with obesity underwent a very-low calorie ketogenic
diet (VLCKD).
Methods: Twenty-one patients with obesity (n ¼ 12 women, 47.9 ± 1.02 yr, 33.0 ± 0.2 kg/m2) after 6
months on a VLCKD and 12 normal weight volunteers (n ¼ 6 women, 50.3 ± 6.2 yrs, 22.7 ± 1.5 kg/m2)
were studied. Data from the Infinium MethylationEPIC BeadChip methylomes of blood leukocytes were
obtained at time points of ketotic phases (basal, maximum ketosis, and out of ketosis) during VLCKD
(n ¼ 10) and at baseline in volunteers (n ¼ 12). Results were further validated by pyrosequencing in
representative cohort of patients on a VLCKD (n ¼ 18) and correlated with gene expression.
Results: After weight reduction by VLCKD, differences were found at 988 CpG sites (786 unique genes).
The VLCKD altered methylation levels in patients with obesity had high resemblance with those from
normal weight volunteers and was concomitant with a downregulation of DNA methyltransferases
(DNMT)1, 3a and 3b. Most of the encoded genes were involved in metabolic processes, protein meta-
bolism, and muscle, organ, and skeletal system development. Novel genes representing the top scoring
associated events were identified, including ZNF331, FGFRL1 (VLCKD-induced weight loss) and CBFA2T3,
C3orf38, JSRP1, and LRFN4 (VLCKD-induced ketosis). Interestingly, ZNF331 and FGFRL1 were validated in
an independent cohort and inversely correlated with gene expression.
Conclusions: The beneficial effects of VLCKD therapy on obesity involve a methylome more suggestive of
normal weight that could be mainly mediated by the VLCKD-induced ketosis rather than weight loss.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Sanitaria, Complejo Hospitalario de Santiago (CHUS), C/ Choupana, S/N, 15706, Santiago de Compostela, Spain.
, endocrine@usc.es (A.B. Crujeiras).
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ketosis has gained interest over recent years due to its induced
benefits that it imparts on several health conditions [1,2]. Ketosis is
associated with a delay in the onset of diseases and increased
longevity [3]. Similarly, ketosis is suggested to have an extensive
range of health benefits, from increased physical endurance in
athletes [4,5] to delayed aging [6]. Also to improve conditions such
as neurodegenerative disease [7e9] cancer [10e12], cardiovascular
disease [13], and obesity [14]. Some of these studies involved high
fat ketogenic diets and even though the main characteristic of
ketogenic diets is the carbohydrates restriction, the specific
composition in macronutrients and calories should be taken into
consideration for the impact in clinical practice [15].
A very-low-calorie-ketogenic diet (VLCKD)was demonstrated to
be an effective strategy in managing obesity [16], including weight
loss and maintenance [17], increased preservation of muscle mass
[18], and enhanced resting metabolic rate [19]. Moreover, it is able
to improve metabolic parameters in patients with obesity [20,21]
and type 2 diabetes [22]. Additionally, it was demonstrated that a
VLCKD is able to reduce food craving and improve psychobiological
parameters to help improve quality of life in patients with obesity
[23]. However, the molecular mechanisms underlying these bene-
fits of ketogenic diet remain unknown.
The main molecular mechanism that links the effect of envi-
ronmental factors, such as nutrition, with the regulation of the
genes function is epigenetics [24]. Indeed, dietary factors or dietary
patterns were identified as modulators of epigenetic mechanisms
[25e28].
Recently, it was suggested that ketone bodies orchestrate gene
expression via epigenomic mechanisms [29]. This molecular effect3960of nutritional ketosis has been reported in neurologic disorders
such as epilepsy [30,31] and Kabuki syndrome and related disor-
ders [32]. The effect of ketone bodies on epigenetic regulation was
also proposed as a potential opportunity for anticancer therapies
[33]. Moreover, ketogenic diets, including dietary restriction, delay
aging through epigenetic effects [34].
On the other hand, obesity is associated with a specific
methylation profile in several tissues [35e38] and the obesity-
related methylome is related to complications such as insulin
resistance [39] and cancer [40,41]. Moreover, several methylation
marks were identified as potential biomarkers for predicting the
success of weight loss therapies during the active phase of treat-
ment [42e46] or during the period of weight loss maintenance
[47,48]. Therefore, DNA methylation was proposed as a target for
preventing and managing obesity [48e51].
In light of the above evidence, the aim of the current study was
to evaluate how a VLCKD might affect the obesity methylome.
Furthermore, this study aimed to identify the changes in the
obesity-related methylome that are mediated by the induced
weight loss or are dependent on ketosis.2. Materials and methods
2.1. Patient cohort
The DNA and RNA for methylation and gene expression assays
were isolated from blood samples of patients from a 6-month
nutritional intervention study performed at the Endocrinology
and Nutrition Department of the Hospital Clinico, Universitario of
Valladolid; the patients were receiving treatment for obesity. In
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analyzed.
The inclusion criteria were: age between 18 and 65 years, body
mass index (BMI) 30 kg/m2, stable body weight over the previous
3 months, a desire to lose weight, and a history of failed dietary
efforts. Themain exclusion criteriawere thyroid alteration, diabetes
mellitus, obesity induced by other endocrine disorders or drugs,
and participation in any active weight-loss program in the previous
3 months. In addition, patients with previous bariatric surgery,
reported or suspected abuse of narcotics or alcohol, severe
depression or any other psychiatric disease, severe hepatic insuf-
ficiency, any type of renal insufficiency or gout episodes, neph-
rolithiasis, neoplasia, previous instances of cardiovascular or
cerebrovascular disease, uncontrolled hypertension, orthostatic
hypotension, and hydroelectrolytic or electrocardiographic alter-
ations were excluded. Females who were pregnant, breastfeeding,
or intending to become pregnant and those with child-bearing
potential who were not using adequate contraceptive methods
were also excluded. Apart from obesity and metabolic syndrome,
participants were generally healthy individuals. Under these
criteria, 21 patients with obesity and 12 volunteers with normal
weight were included in this study.
The study protocol was in accordance with the Declaration of
Helsinki and was approved by the Ethics Committee for Clinical
Research of Hospital Clinico Universitario de Valladolid, Spain (C.I:
40/13, PNK-DHA2013-01). Participants provided written informed
consent before any intervention related to the study. Participants
received no monetary incentives.
2.2. Very-low-calorie ketogenic diet protocol
Patients included in this study derived from a randomized
clinical trial investigating the effect of docosahexaenoic acid (DHA)
supplementation in a very low-calorie ketogenic diet. The clinical
trial consisted in two arms: one armwhere patients follow a VLCKD
and other arms where patients followed a VLCKD þ DHA [21].
Nutritional interventionwas based on a commercial weight-loss
program (PNK method ®), as described elsewhere [18,21]. Briefly,
the intervention included an evaluation by the specialist physician
conducting the study, an assessment by an expert dietician, and
exercise recommendations. This method is based on high-
biological-value protein preparations obtained from cow's milk,
soy, avian eggs, green peas, and cereals. Each protein preparation
contained 15g protein, 4g carbohydrates, 3g fat, and provided
90e100 kcal. The VLCKD þ DHA arm was supplemented with
500 mg/day DHA [21].
The weight-loss program has five steps and adheres to the most
recent guidelines of the EFSA (2015) on total carbohydrate intake
[52]. The first three steps consist of a VLCKD (600e800 kcal/day)
that is low in carbohydrates (<50g daily fromvegetables) and lipids
(only 10g of olive oil per day). The amount of high biological-value
proteins ranged between 0.8 and 1.2g per kg of ideal bodyweight to
ensure that patients were meeting their minimum bodily re-
quirements and to prevent the loss of lean mass. In step 1, the
patients ate high-biological-value protein preparations five times a
day and vegetables with low glycemic indices. In step 2, one of the
protein servings was substituted with a natural protein (e.g., meat
or fish) either at lunch or at dinner. In step 3, a second serving of
low-fat natural protein was substituted for the second serving of
biological protein preparation. Throughout these ketogenic phases,
supplements of vitamins and minerals, such as K, Na, Mg, Ca, and
omega-3 fatty acids, were provided in accordance with interna-
tional recommendations [53]. These three steps were maintained
until the patient lost the target amount of weight, ideally 80%.
Because of this, the ketogenic steps varied in time depending on the3961individual and the weight-loss target. The total ketosis state lasted
for a maximum of 60 days.
In either step 4 or 5, ketosis was ended by the physician in
charge of the patient based on the amount of weight lost, and the
patient began a low-calorie diet (800e1500 kcal/day). At this point,
the patients underwent a progressive incorporation of different
food groups and participated in a program of alimentary re-
education to guarantee long-term maintenance of the weight
loss. The maintenance diet consisted of an eating plan balanced for
carbohydrates, protein, and fat. Depending on the individual, cal-
ories consumed ranged between 1500 and 2000 kcal/day, with the
goal of maintaining the weight loss and promoting a healthy
lifestyle.
During this study, patients followed the steps of themethoduntil
they reached the target weight, or up to a maximum of 4 months of
follow-up, although patients remained under medical supervision
for the following months. Patients visited the research team every
15 ± 2 days to evaluate adherence and potential side effects. Com-
plete anthropometry, body composition, and biochemical assess-
ments were performed at four of the visits, which were determined
according to the evolution of each patient through the steps of
ketosis and weight loss: Visit 1 (Baseline), visit 2 (Maximum
Ketosis), visit 3 (Reduced Ketosis) and visit 4 (Endpoint). DNA
methylationandgeneexpressionwereperformedat visits 1, 2, and4.
In all visits, patients received dietary instructions, individual
supportive counsel, and encouragement to exercise on a regular
basis using a formal exercise program. Additionally, a program of
reinforcement telephone calls was instituted, and a phone number
was provided to all participants to address any concerns.
2.3. Anthropometric assessment
All anthropometric measurements were performed after an
overnight fast (8e10 h) under resting conditions in duplicate and
performed by well-trained health workers. At each visit, patients
wereweighed on the same calibrated scale (Seca 200 scale, Medical
Resources, EPI Inc OH, USA). BMI was calculated as body weight in
kg, divided by the square of body height in meters (BMI ¼ weight
(kg)/height2 (m)). Waist circumference (WC) was measured using a
standard flexible non-elastic metric tape placed over the midpoint
between the last rib and the iliac crest, with the patient standing
and exhaling.
2.4. Determining levels of ketone bodies
Ketosis was determined by measuring ketone bodies, specif-
ically b-hydroxy-butyrate (b-OHB), in capillary blood using a
portable meter (GlucoMen LX Sensor, A. Menarini Diagnostics,
Neuss, Germany; sensitivity <0.2 mmol/l). As with anthropometric
assessments, all determinations of capillary ketonemia were made
after an overnight fast of 8e10 h. These measurements were per-
formed daily by each patient during the entire VLCKD, and the
corresponding values were reviewed using machine memory by
the research team to control adherence. Additionally, b-OHB levels
were determined at each visit by the physician in charge of the
patient.
2.5. DNA methylation analysis
2.5.1. DNA preparation and bisulphite conversion
DNA from fresh-frozen (FF) blood samples was isolated using a
standard phenol-chloroform/proteinase-k protocol according to
the manufacturer's instructions, with slight modifications.
Genomic DNA was isolated from leukocytes using the Mas-
turPure™ DNA purification kit (Epicentre Biotechnologies,
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1 h at 45 C. All DNA samples were quantified using the fluoro-
metric method (Quan-iT PicoGreen DsDNA Assay, Life Technolo-
gies) and were assessed for purity using a NanoDrop (Thermo
Scientific) to determine 260/280 and 260/230 ratio measurements.
The integrity of the FF DNA was verified by electrophoresis in 1.3%
agarose gel. DNA (500 ng) was bisulfite converted using the EZ DNA
methylation kit Methylation-Gold (Zymo Research, CA, USA) ac-
cording to the manufacturer's instructions, which converts non-
methylated cytosine into uracil.
2.5.2. Infinium MethylationEPIC BeadChip
High-quality DNA samples (500 ng) obtained from blood leu-
kocytes of patients included in the VLCKDþ DHA arm of the clinical
trial (discovery cohort; n ¼ 10 patients, 3 paired samples/patient)
were selected for bisulfite conversion (Zymo Research; EZ-96 DNA
Methylation™ Kit) and hybridization to Infinium MethylationEPIC
BeadChip (Illumina) following the Illumina Infinium HD methyl-
ation protocol. DNA quality checks, bisulfite modification, hybridi-
zation, data normalization, statistical filtering, and value
calculations were performed as previously described [54,55].
Whole-genome amplification and hybridization were then
performed on a BeadChip followed by single-base extension and
analysis on a HiScan SQ module (Illumina) to assess cytosine
methylation states. The annotation of CG islands (CGIs) used the
following categorization: 1) shore, for each of the 2-kb sequences
flanking a CGI; 2) shelf, for each of the 2-kb sequences next to a
shore; and 3) open sea, for DNA not included in any of the previous
sequences or in CGIs [54,55]. The transcription start site 200 and
the transcription start site 1500 indicate regions either 200 or 1500
bp from the transcription start site, respectively.
2.5.3. Pyrosequencing analysis
Pyrosequencing was used to assess selected markers in 18 pa-
tients (validation cohort: (n ¼ 7 derived from the discovery cohort
and n ¼ 11 from an independent cohort of patients; 3 paired
samples/patient)). DNA samples analyzed in the validation cohort
were derived from patients included in the two arms of the clinical
trial and merged for the statistical analysis (VLCKD: n ¼ 10;
VLCKD þ DHA: n ¼ 8). The primer sequences used in this analysis
were designed using Qiagen's PyroMark Assay Design 2.0 software
to hybridize to CpG-free sites to ensure methylation-independent
amplification (details and primer sequences are available in
Supplementary Table S1). Genomic DNAwas isolated from FF blood
leukocytes using the MasturPure™ DNA purification kit (Epicentre
Biotechnologies, Madison, WI, USA), according to the manufac-
turer's instructions. DNA methylation analyses were performed
using bisulfite-treated DNA (Zymo Research; EZ-96 DNA Methyl-
ation™ Kit) followed by a highly quantitative analysis based on
PCR-based pyrosequencing using the PyroMark Q24 Systemversion
2.0.7 (Qiagen). Methylation level was expressed as the percentage
of methylated cytosine over the sum of methylated and unmethy-
lated cytosines. Non-CpG cytosine residues were used as built-in
controls to verify bisulfite conversion. The values are expressed as
themean for all sites. We also included human non-methylated and
methylated DNA set as controls in each run (Zymo Research). The
inter-assay precision (%CV) was <2.5%, intra-assay (%CV) was <1.0%.
2.6. Expression assay by qRT-PCR
RNA from blood leukocytes (n ¼ 18 patients) was extracted
using Trizol (Invitrogen) according to the manufacturer's recom-
mendations. The RNA concentrations were measured with a
Nanodrop 2000 spectrophotometer (Thermo Scientific). From total
extracted RNA, 2 mg were DNase treated using a DNA-free kit as a3962template (Ambion) to generate first-strand cDNA synthesis using
the High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). Real-time quantitative polymerase chain reaction (qRT-
PCR) was performed using TaqMan Universal PCR Master Mix,
TaqMan Probes (Applied Biosystems) (details and primer sequences
are available in Supplementary Table S1), and the Step OnePlus
Real-Time PCR System (Applied Biosystems). All experiments were
performed in duplicate, and gene expression levels were normal-
ized to the levels of housekeeping gene GAPDH. The fold change in
gene expression was calculated using the 2DDCt relative quantita-
tion method according to the manufacturer's guidelines (Applied
Biosystems), and data are reported as the geometric mean (SEM).
qRT-PCR experiments were performed in compliance with the
MIQE (Minimum Information for Publication of Quantitative Real-
Time PCR Experiments) guidelines (http://www.rdml.org/miqe).2.7. Statistical analysis
The sample size of the current study was calculated to detect
differences for methylation levels taking into account published
values of epigenome-wide analysis in the field of obesity [35,40,41].
The interventional differences were examined in two independent
cohorts. Microarray-based DNA methylation analysis was per-
formed in the discovery cohort (n ¼ 10 patients; 3 paired samples/
patient), and then the identified genes were validated in an inde-
pendent cohort of patients (validation cohort; n ¼ 18 patients; 3
paired samples/patient). Finally, the association between DNA
methylation level of the identified CpG sites and the anthropo-
metric or biochemical parameters was assessed in the global cohort
of patients included in this study (n ¼ 28).
The methylation level of each cytosine was expressed as a b
value, which was calculated as the fluorescence intensity ratio of
the methylated to the unmethylated version of the probe. b values
ranged between 0 (unmethylated) and 1 (completely methylated)
according to the combination of the Cy3 and Cy5 fluorescence in-
tensities. Color balance adjustment and normalization were per-
formed to normalize the samples between the two-color channels
using Genome Studio Illumina software (V2010.3). Genome Studio
normalizes data using different internal controls that are present
on the Infinium MethylationEPIC BeadChip. This software also
normalized data depending on internal background probes [55]. b
values with detected p-values > 0.01 were considered to fall below
the minimum intensity and threshold, and these CpGs were
consequently removed from further analysis. Additionally, probes
that contained single nucleotide polymorphisms (SNPs) at the 10
bp 30 end of the interrogating probe were filtered out. To identify
consistent patterns of DMCpGs due to the nutritional intervention,
a linear model was fitted using a B-spline approximation [56].
Three linear models were fitted: Model 1 was fitted by including
the three points of the nutritional intervention to evaluate the
general effect of VLCKD; Model 2 including baseline and maximum
ketosis to evaluate the effect of ketosis and weight loss; Model 3
including methylation levels at maximum ketosis and endpoint to
evaluate the effect of only weight loss, without ketosis. P values
were adjusted for multiple comparisons using the false discovery
rate (FDR) procedure of Benjamini and Hochberg, and results were
considered statistically significant when FDR < 0.10. Additionally,
we applied a threshold for the significant sites based on the mean
difference between visits with a minimum b value change of ±0.02.
Euclidean cluster analysis of significant CpGs was performed using
a heatmap function. The global methylation level was compared
between the nutritional intervention visits by univariant ANOVA
and a Bonferroni post-hoc analysis. All of the aforementioned sta-
tistical analyses were performed using R software (version 3.2.0).
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metric test was performed using the GOstats package on the bio-
logical processes defined by gene ontology (GO) [57]. This analysis
detected significant over-representation of GO terms in one set (i.e.,
list of identified genes) with respect to the entire genome. GO terms
with an adjusted p-value < 0.05 were considered significant.
With SPSS version 21.0 software (SPSS Inc., Chicago, IL) for Win-
dows XP (Microsoft, Redmond, WA), the genomic distribution of the
differentiallymethylatedCpGswas comparedwith thedistributionof
the CpGs from all analyzed sites on the Infinium MethylationEPIC
BeadChip. P values were computed using the chi-square test to
determine over- or under-representation of the CpGs. The potential
association between anthropometric or biochemical parameters and
DNAmethylation levels (b-values)was evaluatedusing the Spearman
coefficient test. Differences inDNAmethylation levels and expression
of the identifiedgenes during the time-course of the intervention and
between the nutritional intervention visitswere assessedby thenon-
parametric tests, Kruskal Wallis and ManneWhitney U, respectively.
P  0.05 was considered statistically significant.3. Results
3.1. Patient characteristics
Samples from a total of 21 patients who followed the nutritional
intervention based on a VLCKD were compared with samples from
12 healthy volunteers with normal weight and evaluated in this
study (Supplemental Fig. 1). We first evaluated the discovery cohort
(n ¼ 10 participants with obesity who followed a VLCKD þ DHA
(n ¼ 5 women) and n ¼ 12 (6 women) volunteers with normal
weight). An extended validation cohort composed of 11 patients (7
women) with obesity that followed a VLCKD þ DHA or a VLCKD-
DHA was also analyzed. Statistically significant differences were
not observed between either cohort in age, gender, height, body
weight, BMI, waist circumference, ketosis, or the response to
weight loss treatment (Table 1). Differences statistically significant
were only detected in body weight, BMI and waist circumference
between patients with obesity and subjects with normal weight
(Table 1). All patients lost weight after nutritional intervention
(21.8 ± 4.9%), together with reductions in BMI (21.9 ± 5.1%) and
waist circumference (19.3 ± 4.4%).Table 1












N 12 10 10 10
Age (years) 50.3 ± 6.2 48.8 ± 9.20 e e
Gender (men/women) 6/6 5/5 e e
Height (m) 1.67 ± 0.08 1.68 ± 0.08 e e
Body weight (Kg) 63.8 ± 8.7 93.4 ± 9.9a 84.3 ± 8.4 73.9 ± 6.7b
BMI (Kg/m2) 22.7 ± 1.49 32.9 ± 1.4a 29.8 ± 1.7 26.1 ± 1.8b
Waist circumference (cm) 77.4 ± 7.2 111.1 ± 6.6a 102.3 ± 7.4 90.2 ± 3.1b
Ketonemia (mM) — 0.15 ± 0.07 2.11 ± 1.11b 0.15 ± 0.07
Weight loss (%) e e 9.69 ± 2.51 20.58 ± 5.17c
Data shown are mean ± SD (standard deviation).* The sample size of the validation cohor
an independent cohort.
Abbreviations: VLCKD, very-low-calorie ketogenic diet.
a Statistically significant differences compared with control Normal weight in discove
b Statistically significant differences compared with Baseline in both cohorts.
c Statistically significant differences compared with Maximum Ketosis in both cohorts
39633.2. DNA methylation changes during the global VLCKD
intervention
DNA methylation profiles of blood leukocytes involving
approximately 850 thousand CpGs were analyzed after VLCKD
intervention. This analysis revealed statistically significant differ-
ences (cut-off point D  0.02; FDR  0.10) at 988 CpG sites, from a
total of 739,222 valid CpGs (see detailed list in Supplementary
Table S2). The differentially methylated CpGs were mostly charac-
terized as changes towards CpG hypomethylation occurring after
nutritional intervention, in both total DMCpGs (Fig. 1A) and in the
DMCpGs located in promoters, and islands or shores (Fig. 1B). This
result of global hypomethylation was correlated with the down-
regulation in the expression of DNA methyltransferase (DNMT) 1
and the de novo methyltransferases DNMT3A and DNMT3B (Fig. 1C
and Supplemental Fig. 2).
The identified CpG sites mapped to 786 unique genes and we
were able to separate the samples according to nutritional inter-
vention visits using a hierarchical cluster approach (Fig. 1D). It
should be noted that the methylation levels of the 988 CpG sites
differentially methylated after nutritional intervention were
altered to resemble methylation levels observed in samples from
subjects with normal weight (Fig. 1C). The 20 DMCpGs with the
highest difference with respect to baseline among genes that are
represented by more than 2 CpGs are represented in Table 2.
Regarding the functional distribution (Fig. 2), the differences in
DNA methylation were mainly observed in open sea regions
(Fig. 2A), with 43.2% of the DMCpG sites located in promoter re-
gions and the majority of DMCpGs in the body (Fig. 2B). Moreover,
the DMCpGswere mainly found in chromosomes 2, 9, 16,17,19, and
22 when compared with all CpGs analyzed (Fig. 2C).
Among the 988 DMCpGs, we found 886 (89.7%) with
decreased and 102 (10.32%) with increased levels of DNA
methylation after nutritional intervention. Moreover, the
DMCpGs that lost methylation with respect to baseline were
located mainly in the open sea (Fig. 2D) and body (Fig. 2E). In
contrast, the DMCpGs that gained methylation after the nutri-
tional intervention were mostly located in promoters (TSS 200
and 1st exon) (Fig. 2D) and in CpG islands (Fig. 2E). Regarding
chromosome distribution, the DMCpGs with decreased methyl-
ation levels after nutritional treatment were found on chromo-
somes 1, 4, 6 7, 8, 9, 14, and 16, whereas DMCpGs with increased.









Adiposity Time Cohort Time x
Cohort
18* 18 18 e e e e
47.1 ± 9.8 e e 0.654 e 0.678 e
7/11 e e e e e e
1.65 ± 0.10 e e 0.773 e 0.446 e
90.8 ± 11.6 81.9 ± 10.4 70.4 ± 10.4b <0.0001 <0.001 0.488 0.649
33.2 ± 1.7 30.06 ± 1.7 25.7 ± 1.7b <0.0001 <0.001 0.986 0.334
108.3 ± 8.5 100.1 ± 7.3 86.9 ± 7.4b <0.0001 <0.001 0.325 0.836
0.18 ± 0.08 1.71 ± 1.08b 0.18 ± 0.08 e <0.0001 0.445 0.374
e 9.80 ± 1.99 22.52 ± 4.75c e <0.0001 0.336 0.455
t was completed with n ¼ 7 patients from the discovery cohort and 11 patients from
ry cohort.
.
Fig. 1. Profile of DNA methylation following the VLCKD (n ¼ 10; Discovery cohort). (A). Global differences in methylation levels of 988 DMCpGs identified by Infinium
MethylationEPIC BeadChip analysis. (B). Global differences in methylation levels of DMCpGs located in the promoter and island/shore. (C). Expression levels of DNA methyl-
transferase (DNMT) 1 and the de novo methyltransferases DNMT3A and DNMT3B (D). Supervised clustering of the 988 CpGs that were found to be differentially methylated
between patients with obesity and healthy volunteers with normal weight (n ¼ 12) groups. The identified CpG sites mapped to 786 unique genes. Differences statistically significant
detected (P < 0.0001). DMCpGs, differentially methylated CpGs; VLCKD, very-low calorie ketogenic diet.
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11, 12, 17, 21, and 22 (Fig. 2F).
3.3. Biological significance of the dietary intervention-related
DMCpG sites and associated genes
Interestingly, most differentially methylated genes belonged to
a network significantly enriched in protein interactions (p < 0.001)
according to STRING analysis (Fig. 3A). GO analysis was performed
to test whether certain molecular functions or biological processes
were significantly enriched within the 786 genes associated with
the 988 DMCpGs discovered through VLCKD intervention (Fig. 3B).
Among the categories of functional processes that exhibited sta-
tistical significance (FDR < 0.05), we found processes related to
regulation of transcription, signal transduction, cell differentiation,
proliferation and apoptosis, metabolic processes, response to hyp-
oxia, protein processing, muscle organ and skeletal system devel-
opment, nervous system development and axon guidance (Fig. 3B).
Among these, we highlighted relevant pathways in the field of
obesity physiopathology such as insulin signaling, protein digestion
and absorption, adipocytokine signaling and muscle development
(Fig. 4AeD). To investigate biological relevance, the CpG sites3964representing promoter regions (TSS1500, TSS200, 50 UTR and 1st
Exon) at CpG islands/shores were selected. This selection yielded
141 CpGs representing 150 unique genes. Based on this filter we
identified CpG sites that could be genetic targets whose methyl-
ation is associated with VLCKD responses. Among these, the most
representative gene was ZNF331, which was represented by 2 CpG
sites located in the promoter and island with the highest difference
with respect to baseline. Furthermore, FGFRL1 was also selected
from among the DMCpG sites because of its biological relevance in
metabolic pathways and obesity pathogenesis and because the
methylation level of this gene in leukocytes was previously pro-
posed as an episignature that mirrors methylation levels of
dysfunctional adipose tissue in obesity [35].
3.4. DNA methylation changes associated with the effects of
dietary-induced ketosis
An analysis comparing baseline (day 0) with maximum ketosis
(day 30) yielded 1365 DMCpGs. With respect to all CpGs analyzed,
these CpGs were found mainly in the open sea (Fig. 5A) and body
(Fig. 5B) and in chromosomes 1, 10, 11, 17, 19, and 22 (Fig. 5C). The
DMCpGs that gained methylation were found in the island and
Table 2
List of DMCpGs with the highest differences for Baseline - Maximum Ketosis - Endpoint between genes that are represented by more than 2 CpGs.
TargetID CHR Position Gene Name Gene region CpG context Methylation levels (mean) Differences p value FDR
B MK E MK - B E  B
cg04254103 19 1794380 ATP8B3; ATP8B3;
ATP8B3
Body; Body; Body N_Shore 0.826 0.786 0.796 0.039 0.030 0.001 0.091




0.782 0.741 0.748 0.040 0.034 0.001 0.099
cg12063937 1 7731375 CAMTA1 Body 0.837 0.785 0.802 0.051 0.034 0.000 0.054
cg00035197 16 88962986 CBFA2T3; CBFA2T3 Body; Body Island 0.803 0.748 0.763 0.056 0.040 0.001 0.082
cg09962824 21 44479417 CBS Body N_Shore 0.754 0.707 0.714 0.047 0.040 0.000 0.051





0.846 0.814 0.820 0.032 0.026 0.001 0.095
cg26493726 19 36508614 CLIP3 Body S_Shelf 0.808 0.771 0.773 0.037 0.035 0.000 0.069
cg01818220 9 23821773 ELAVL2; ELAVL2;
ELAVL2;
ELAVL2
50UTR; TSS1500 Island 0.092 0.148 0.134 0.056 0.042 0.000 0.008
cg01933710 5 132596864 FSTL4 Body 0.828 0.778 0.799 0.049 0.029 0.001 0.076
cg07390459 2 121582002 GLI2 Body 0.768 0.720 0.727 0.048 0.041 0.001 0.097
cg14777822 2 121728297 GLI2 Body 0.770 0.728 0.726 0.042 0.044 0.001 0.093
cg16120742 7 50345049 IKZF1 50UTR S_Shore 0.114 0.058 0.041 0.057 0.073 0.000 0.026
cg02999309 10 134502626 INPP5A Body N_Shore 0.836 0.799 0.807 0.037 0.029 0.000 0.024
cg14010696 19 5119250 KDM4B Body Island 0.853 0.812 0.819 0.041 0.034 0.000 0.008
cg16333587 14 101369826 MEG8 Body 0.857 0.817 0.828 0.040 0.029 0.000 0.051
cg20963002 14 101360088 MEG8 TSS1500 0.862 0.821 0.828 0.041 0.034 0.001 0.098




0.884 0.851 0.857 0.033 0.027 0.000 0.051
cg01764953 11 70814657 SHANK2 Body 0.914 0.887 0.887 0.027 0.026 0.000 0.067




Island 0.379 0.431 0.447 0.052 0.068 0.000 0.015






Island 0.397 0.445 0.458 0.048 0.061 0.000 0.019
Data shown are mean.
Abbreviations: B, baseline; CHR, chromosome; E, endpoint; FDR, false discovery rate; MK, maximum ketosis.
Fig. 2. Characterization of the DMCpGs after VLCKD in the discovery cohort (n ¼ 10). (A) Genomic distribution of the DMCpGs and their respective locations regarding the
broader CpG context, (B) gene region and (C) chromosome. (D) Genomic distribution of DMCpGs comparing those that exhibited an increase with those that exhibited a decrease in
methylation levels following VLCKD, and their respective locations in the broader CpG context, (E) the gene region and (F) chromosome. DMCpGs, differentially methylated CpGs;
VLCKD, very-low calorie ketogenic diet.
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Fig. 3. Biological implications of the DMCpGs following a VLCKD. (A) Summary of the GO analysis of the biological process categories representing the differentially methylated
genes associated with DMCpG sites. (B) Gene-protein interaction network-STRING analysis. Most of the genes regulated by methylation belonged to a network significantly enriched
in protein interactions (p < 0.001) according to STRING analysis. DMCpGs, differentially methylated CpGs; GO, gene ontology; VLCKD, very-low calorie ketogenic diet.
Fig. 4. Genes with known functions that present DMCpGs following a VLCKD. (A) Novel genes epigenetically regulated following VLCKD belonged to the insulin signaling
pathway, (B) adipocytokine signaling pathway, (C) protein digestion and absorption functions, and (D) muscle organ development functions. DNA methylation values are expressed
as b-values from the Infinium MethylationEPIC BeadChip. *Denotes differences statistically significant (P < 0.05). DMCpGs, differentially methylated CpGs; VLCKD, very-low calorie
ketogenic diet.
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Fig. 5. Characterization of the DMCpGs during ketosis induced by a VLCKD from the discovery cohort (n ¼ 10). (A) Genomic distribution of the DMCpGs and their respective
locations regarding the broader CpG context, (B) gene region and (C) chromosome. (D) Genomic distribution of DMCpGs comparing those that exhibited an increase with those that
exhibited a decrease in methylation levels during the VLCKD-induced ketosis and their respective locations in the broader CpG context, (E) the gene region and (F) chromosome.
DMCpGs, differentially methylated CpGs; VLCKD, very-low calorie ketogenic diet.
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lost methylation were found in the open sea and body and in
chromosomes 9, 10, 11, 12, 17, 21, 22 (Fig. 5DeF).
With the aim of isolating the specific effects of ketosis on
methylation profile, additional analysis was performed. A Venn
diagram was created by including: DMCpGs Baseline eMaximum
Ketosis ¼ 1365, DMCpGs Baseline e Endpoint ¼ 405, and DMCpGs
Maximum Ketosis e Endpoint ¼ 21. Using these conditions, we
identified 280 CpGs whose methylation was affected by the
induced weight loss per se (see detailed list in Supplementary
Table S3) and 1239 CpGs were identified as VLCKD-induced
ketosis-related DMCpGs (Fig. 6A). These VLCKD-induced ketosis-
related DMCpGs corresponded to 966 annotated genes, and 161 of
these were represented by 137 VLCKD-induced ketosis-related
DMCpGs located in the promoter and island or shore (see detailed
list in Supplementary Table S4). Among the categories ofFig. 6. Biological implications of the DMCpGs related to VLCKD-induced ketosis. (A) Ven
baseline and endpoint, and between maximum ketosis and endpoint. From this analysis, 123
analysis of the biological process categories representing the differentially methylated ge
methylated CpGs; GO, gene ontology; VLCKD, very-low calorie ketogenic diet.
3967functional processes that exhibited statistical significance
(FDR < 0.05), we found processes related to regulation of tran-
scription, signal transduction, cell adhesion, cell differentiation,
proliferation and apoptosis, as well as nervous system develop-
ment and axon guidance. Moreover, these ketosis-related differ-
entially methylated genes belonged to pathways involved in focal
adhesion, insulin and adipocytokine signaling pathways, MAPK
and P53 signaling pathways and in cancer and type II diabetes
mellitus-related pathways (Fig. 6B). Overall pathways associated
with obesity physiopathology.
Among these, we highlighted relevant pathways in the field of
obesity physiopathology such as insulin signaling, protein diges-
tion and absorption, adipocytokine signaling and muscle
development.
To identify potentially novel signatures of DNA methylation
associated with VLCKD-induced ketosis, those genes with moren diagram of the DMCpGs detected between baseline and maximum ketosis, between
9 CpGs were identified as nutritional ketosis-related DMCpGs. (B) Summary of the GO
nes associated with nutritional ketosis-related DMCpG sites. DMCpGs, differentially
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difference in b-values  |2|% were selected. Based on these criteria,
12 genes were identified and are listed in Table 3. When the list was
further filtered by promoter region, the genes CBFA2T3, C3orf38,
JSRP1, and LRFN4 showed at least one VLCKD-induced ketosis-
related DMCpG located in the promoter and island/shore.
3.5. Validation of candidate genes in a representative cohort
We used pyrosequencing, a technique that is most feasible for
studies of patients in hospitals, to evaluate the DNA methylation
levels of ZNF331 and FGFRL1 in an independent cohort of samples
from leukocytes (validation cohort; n ¼ 18 patients who follow a
VLCKD þ DHA or VLCKD-DHA merged Table 1).
Statistically significant differences were found in the methyl-
ation levels after nutritional intervention with respect to baseline
(Fig. 7A). After weight loss treatment, a statistically significant in-
crease with respect to baseline was observed during maximal
ketosis in the 4 CpGs evaluated (p ¼ 0.049). However, no statisti-
cally significant changes were observed in FGFRL1 methylation
levels after the weight loss treatment (Fig. 7B).
DNA methylation has previously been associated with tran-
scriptional repression [58,59]. Accordingly, the expressions of
ZNF331 (Fig. 7C) and FGFRL1 (Fig. 7D) were evaluated. A statistically
significant downregulation in the expression of ZNF331 was found
after nutritional intervention, while the expression of FGFRL1 was
upregulated, especially at maximum ketosis compared with base-
line. Even though the results for methylation level of FGFRL1 were
not validated in the independent cohort, the expression of this gene
was inversely correlated with the methylation levels observed in
the discovery cohort. Overall, these results suggest that epigenetic
regulation of ZNF331 and FGFRL1 related toweight loss could have a
relevant biological function.
The validation part of the current study was performed by
merged the two arms of the clinical trial because the initial results
revealed that botharms induced similarweight loss andketosis [21],
the main outcome used to evaluate changes in the methylome.
Indeed, a further analysis in the validation cohort keeping the two
arms separated, showed that the trend in the methylation levels
through the interventionwas similar to that observed in themerged
analysis for the studied genes, ZNF331 and FGFRL1 (Supplemental
Fig. 3). Differences through the intervention appeared to be higher
in the VLCKD þ DHA than in the VLCKD arm; however, a repeated
measured ANOVA analysis depending on arm showed statistically
significance only for the time-course of the intervention in ZNF331
methylation levels (p < 0.01), without statistically significance for
the interaction between time x arm, nor between the two arms
(p > 0.05).
4. Discussion
In this study, we carried out an epigenome-wide association
study (EWAS) with a longitudinal approach to evaluate the effects
of a ketogenic nutritional intervention for weight-loss (based on a
very-low-calorie ketogenic diet (VLCKD)) on DNA methylation
levels in patients with obesity. As far as we know, this is the first
study performed that evaluated the effects of a ketogenic diet,
particularly a low fat-low carbohydrate ketogenic diet, to treat
obesity on the pattern of DNA methylation. This analysis was per-
formed using an array-based platform that interrogates 850.000
specific CpG sites. Using this design, 988 CpG sites exhibited dif-
ferential methylation after VLCKD intervention. These CpG sites
encoded 786 genes belonging to biological processes involved in
the function of adipose tissue, neurological function, muscle
development, and others metabolic processes. In particular, the3968methylation profile of DMCpGs after a short-period of dieting was
similar to the profile observed in normal-weight individuals. A
global hypomethylation was observed in the DMCpGs identified
correlated with a downregulation in the DNA methyltransferase
(DNMT) family, which are DNA-modifying enzymes that play a
crucial role in regulation of DNA methylation [60]. These effects
were observed from the acute phase of this nutritional intervention
characterized by an induced ketosis state. We identified 1239 CpG
sites that weremodified by a short-time andmoderate ketosis state
per se, independently of the magnitude of weight loss. Therefore,
changes in DNA methylation profile after VLCKD could be related
with the beneficial effects of this kind of nutritional therapy on
body weight and body composition [18], biochemical and hor-
monal parameters [20,61], and quality of life [23] and promoted
mainly by the induced ketosis state.
In our longitudinal study after weight reduction, there were
changes in methylation levels of genes involved in the insulin
signaling pathway, such as HRAS, RPTOR, INSR, ACACB, MKNK2,
PRKCZ, TSC2, and PRKAG2; Collagen-related genes such as COL9A2,
COL1A1, and COL5A1 as well as, genes involved in adipocyte
signaling such as CHUK, TRAF2, CAMKK1, ACACB, RELA, and PRKAG2.
These results endorse the hypothesis of epigenetic regulation of
adipose tissue dysfunction in obesity as it was previously observed
in visceral adipose tissue [39].
The current study also revealed an epigenetic effect of treat-
ment with a VLCKD on genes associated with muscle development
such as CACNA1H, LAMA2, SMTN, SGCB, ZFHX3, CENPF, AEBP1, and
CHAT. Muscle is an important tissue in the pathogenesis of obesity,
which is directly linked with morbidity and mortality in humans
[59,62,63]. It has been demonstrated that a VLCKD is able to
preserve the mass and function of muscle [18], as well as modulate
the secretion of specific myokines [61]. The current study dem-
onstrates that these effects could be mediated by epigenetic
mechanisms.
The most relevant characteristic of epigenetic regulation is
plasticity [64]. However, a cross-sectional approach is unable to
evaluate the potential reversibility of obesity-related epigenetic
marks and causal interferences. With this study, we could identify
that the methylation levels of most of the DMCpGS after VLCKD
were similar to that observed in normal weight patients.
Importantly, the achieved results in this study after VLCKD
were representative of the more acute phase, during a short
period (<60 days) and moderate intensity VLCKD-induced
ketosis state. In fact, a specific methylome was observed inde-
pendent of weight loss induced by VLCKD intervention. Among
the encoded genes, CBFA2T3 (also called MTG16) was the most
represented, with 4 CpGs differentially methylated and JSRP1,
represented by 2 CpGs in the promoter region. Ketone bodies
have previously been described as important signaling molecules
[65] and were proposed to be able to modulate epigenetic
mechanisms [66]. Molecular and cell biology assays showed
CBFA2T3 to have characteristics consistent with a tumor sup-
pressor [67] that lead to decreased glycolysis and stimulated
mitochondrial respiration, and therefore may induce a
Warburgelike effect [68] which is consistent with ketosis. This
finding further relevant considering that obesity is a risk factor
for cancer development [69,70]. On The other hand, JSRP1 was
associated with pathways involving skeletal muscle excitation-
contraction [71]. If we consider that often methylation in the
gene promoter regions implies reductions in gene expression
[58,59,72], the lower methylation levels observed for CBFA2T3
and JSRP1 could lead to higher expression of these genes, with
consequent improvements in mitochondrial and muscle function,
respectively. However, until now there have been no studies
regarding the role of these genes in the context of energy
Table 3
List of DMCpGs with the highest differences for Baseline - Maximum Ketosis between genes that are represented by more than 2 CpGs.
Target Id Gene name Function Disease
Annotation
CHR Position Gene region CpG Context Methylation levels p value FDR
B MK
Mean SD Mean SD
cg10143842 C3orf38 No items found 3 88198517 TSS1500 Island 0.066 0.114 0.024 0.024 0.001 0.096
cg24029436 3 88199835 Body S_Shore 0.113 0.105 0.059 0.038 0.000 0.018














16 88962986 Body; Body Island 0.803 0.041 0.748 0.036 0.000 0.051
cg01977582 16 88976280 50UTR; Body S_Shore 0.812 0.031 0.782 0.012 0.001 0.094
cg07243576 16 88973245 50UTR; Body N_Shelf 0.849 0.028 0.817 0.017 0.001 0.098
cg27102297 16 88966903 Body; Body S_Shore 0.767 0.032 0.731 0.023 0.001 0.088

















21 44486298 Body Island 0.873 0.012 0.852 0.014 0.000 0.077
cg09962824 21 44479417 Body N_Shore 0.748 0.037 0.706 0.031 0.000 0.044









9 137634551 Body; Body 0.825 0.023 0.775 0.033 0.000 0.025
cg13714791 9 137694578 Body S_Shore 0.839 0.025 0.813 0.024 0.001 0.096






7 216899 Body N_Shore 0.857 0.014 0.836 0.013 0.000 0.046
cg11554153 7 209165 Body S_Shore 0.821 0.020 0.788 0.017 0.000 0.052
cg17915125 INPP5A protein binding and
PH domain binding
10 134476336 Body N_Shore 0.879 0.020 0.852 0.011 0.000 0.079
cg02999309 10 134502626 Body N_Shore 0.836 0.024 0.799 0.020 0.000 0.021
cg10356204 JSRP1 skeletal muscle
contraction
19 2255744 TSS1500 S_Shore 0.697 0.040 0.654 0.032 0.001 0.099





11 17803160 Body S_Shore 0.834 0.030 0.803 0.019 0.000 0.069
cg23787205 11 17801046 Body Island 0.894 0.031 0.869 0.016 0.000 0.086
cg03214876 KIAA1875 No items found 8 145166631 Body S_Shore 0.875 0.019 0.843 0.013 0.000 0.006
cg11202914 8 145172221 Body S_Shore 0.905 0.017 0.886 0.010 0.000 0.010
cg12378449 LRFN4 protein binding 11 66627382 Body; Body; Body; Body N_Shore 0.780 0.036 0.742 0.023 0.001 0.097
cg19391515 11 66626563 Body; Body;
1stExon; Body
Island 0.812 0.025 0.785 0.015 0.000 0.032
cg12378449 PC protein binding Pyruvate
carboxylase
deficiency
11 66627382 Body; Body; Body; Body N_Shore 0.780 0.036 0.742 0.023 0.001 0.097
cg19391515 11 66626563 Body; Body;
1stExon; Body
Island 0.812 0.025 0.785 0.015 0.000 0.032
cg16014906 STK32C No items found 10 134095321 Body N_Shore 0.841 0.023 0.819 0.019 0.000 0.070
cg24305451 10 134021178 30UTR S_Shore 0.843 0.035 0.810 0.030 0.001 0.091
Data shown are mean ± SD (standard deviation).
Abbreviations: B, baseline; CHR, chromosome; FDR, false discovery rate; MK, maximum ketosis.
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regulation by ketone bodies-induced epigenetic regulation. The
current results warrant further investigation on this topic.
To strengthen these findings and to explore the relationship
between methylation levels and the expression of the identified
genes, we analyzed the methylation and expression of ZNF331 and3969FGFRL1 in an independent cohort. These genes belong to a family of
genes associated with adipogenesis [73], T2D, insulin resistance
[74,75], and obesity-related cancer [40,41], and their methylation
levels of its sequence could be part of an obesity-related epis-
ignature as previously proposed [35]. Even though the role of these
genes in body weight homeostasis requires further elucidation, the
Fig. 7. DNA methylation of ZNF331 and FGFRL1 is inversely associated with gene expression. DNA methylation differences for ZNF331 (A) and FGFRL1 (B) after VLCKD in the
validation cohort (n ¼ 18) as measured by pyrosequencing. Differential gene expression of ZNF331 (C) and FGFRL1 (D) after VLCKD in the validation cohort (n ¼ 18). *Denotes
differences statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001). VLCKD, very-low calorie ketogenic diet.
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suggest its epigenetic regulation may be a novel mechanism
involved in the management obesity.
A strength of this study is its longitudinal design. With this
design, we could evidence for the first time an association between
ketosis and DNA methylation independent of weight loss. Despite
the tissue specificity of DNA methylation, we were able to detect
time-course changes in methylation levels of genes involved in
adipose and muscle physiopathology using an easy to obtain tissue
for serial sampling in a clinical setting. The relatively small sample
size is one limitation of this study. However, as each subject un-
derwent 3 evaluations and the results were subjected to paired
analysis, statistical power was increased and real differences were
observed between experimental points. Moreover, subsequent
analyses were performed with highly stringent filters to produce
consistent results, which were further validated in an independent
cohort. In addition, although the magnitude of the DNA methyl-
ation differences after nutritional intervention could be considered
small, these differences may have been due to the use of a mix of
blood cells as opposed to single cell analysis, and also because of
the short follow-up period used (6 months of weight loss and 30
days of ketosis state), which further increases the relevance of the
findings as they were detected even with such a short clinical
course. Longer-term prospective studies are needed to confirm the
association between DNA methylation levels in blood leukocytes
and weight loss response to a VLCKD, and more particularly, the
role of ketosis in the regulation of epigenetic mechanisms such as
DNA methylation. This study provides information that could be
valuable and useful in the context of eomics and big data era to
assess both potential benefits and adverse effects of therapeutic
agents [76], such as ketone bodies to counteract obesity.
In conclusion, this study demonstrates for the first time that the
beneficial effects of VLCKD therapy in reducing obesity involve
epigenetic mechanisms. Because the effect was observed in the
more acute phase of the nutritional intervention, this epigenetic3970effect could be mainly mediated by ketosis induced by the VLCKD.
Further studies are needed to evaluate whether the DNA methyl-
ation markers identified could be useful in predicting the success of
this intervention in the context of personalized medicine.
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